HighGravityDataGilead Sciences — Apr 24, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000882095-25-000009
Showing in the filing
Non-GAAP diluted EPS
“$ 7.70” – “$ 8.10”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 18
Product sales for FY2025
“$ 28,200” – “$ 28,600”
Product sales
“$ 28,200”
Product sales excluding Veklury for FY2025
“$ 26,800” – “$ 27,200”
Product sales excluding Veklury
“$ 26,800”
Veklury (High End) for FY2025
“$ 1,400”
Veklury
“$ 1,400”
Diluted EPS for FY2025
“$ 5.65” – “$ 6.05”
Diluted EPS
“$ 5.65”
Non-GAAP diluted EPS for FY2025
“$ 7.70” – “$ 8.10”
Non-GAAP diluted EPS
“$ 7.70”
Quarterly dividend declared for Q2 2025 for Q2 FY2025
“$0.79 per share of common stock”
Quarterly dividend of common stock for Q2 FY2025
“$0.79 per share”
GAAP projected product gross margin for FY2025
“77.0% - 78.0%”
Non-GAAP projected product gross margin for FY2025
“85.0% - 86.0%”
GAAP projected operating income for FY2025
“$10,200 - $10,700”
Non-GAAP projected operating income for FY2025
“$12,700 - $13,200”
GAAP projected effective tax rate for FY2025
“~ 21%”
Non-GAAP projected effective tax rate for FY2025
“~ 19%”
Exhibit 99.1 · the passage around this item
… earlier in the release
April 24, 2025 3 Guidance and Outlook For the full-year, Gilead expects: (in millions, except per share amounts) April 24, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,200 $ 28,600 Unchanged Product sales excluding Veklury $ 26,800 $ 27,200 Unchanged Veklury $ 1,400 $ 1,400 Unchanged Diluted EPS $ 5.65 $ 6.05 Previously $5.95 to $6.35 Non-GAAP diluted EPS $ 7.70 $ 8.10 Unchanged Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below. Key Updates Since Our Last Quarterly Release Virology • Announced FDA accepted New Drug Application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a PDUFA date of June 19, 2025. • Announced the European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention, which will undergo parallel reviews under an Accelerated Assessment timeline. • Presented initial Phase 1 data evaluating investigational once-yearly lenacapavir for HIV prevention at the Conference on Retroviruses and Opportunistic Infections (“CROI”), and announced plans to launch a Phase 3 study in the second half of 2025. • Presented HIV treatment research data at CROI, including long-term outcomes evaluating the use of Biktarvy in people with HIV/HBV coinfection and the primary results of a Phas
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.